Relevance of
Fluorodopa F 18
Machine learning
Parkinson's disease
Positron-emission tomography
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
13 Feb 2023
13 Feb 2023
Historique:
received:
18
11
2022
accepted:
02
02
2023
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
To decipher the relevance of visual and semi-quantitative 6-fluoro-(18F)-L-DOPA ( A total of 110 consecutive patients (48 IPD and 62 controls) with 11 months of median clinical follow-up (reference standard) were included. A composite visual assessment from five independent nuclear imaging readers, together with striatal standard uptake value (SUV) to occipital SUV ratio, striatal gradients and putamen asymmetry-based semi-quantitative PET metrics automatically extracted used to train machine learning models to classify IPD versus controls. Using a ratio of 70/30 for training and testing sets, respectively, five classification models-k-NN, LogRegression, support vector machine, random forest and gradient boosting-were trained by using 100 times repeated nested cross-validation procedures. From the best model on average, the contribution of PET parameters was deciphered using the Shapley additive explanations method (SHAP). Cross-validated receiver operating characteristic curves (cv-ROC) of the most contributive PET parameters were finally estimated and compared. The best machine learning model (k-NN) provided final cv-ROC of 0.81. According to SHAP analyses, visual PET metric was the most important contributor to the model overall performance, followed by the minimum between left and right striatal to occipital SUV ratio. The 10-time cv-ROC curves of visual, min SUVr or both showed quite similar performance (mean area under the ROC of 0.81, 0.81 and 0.79, respectively, for visual, min SUVr or both). Visual expert analysis remains the most relevant parameter to predict IPD diagnosis at 11 months of median clinical follow-up in
Identifiants
pubmed: 36780091
doi: 10.1186/s13550-023-00962-x
pii: 10.1186/s13550-023-00962-x
pmc: PMC9925664
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Informations de copyright
© 2023. The Author(s).
Références
IEEE Trans Med Imaging. 1998 Feb;17(1):87-97
pubmed: 9617910
BMC Med. 2015 Jan 06;13:1
pubmed: 25563062
Neurobiol Aging. 2012 Jun;33(6):1127.e11-20
pubmed: 22226489
Neuroimage Clin. 2020;25:102161
pubmed: 31981888
Ann Neurol. 2017 Dec;82(6):873-882
pubmed: 29165839
Med Phys. 2014 Jan;41(1):012502
pubmed: 24387526
Front Neurosci. 2019 Apr 29;13:396
pubmed: 31110472
NPJ Parkinsons Dis. 2021 Jul 8;7(1):57
pubmed: 34238927
Mov Disord. 2003 May;18(5):467-86
pubmed: 12722160
Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1550-9
pubmed: 21553090
J Nucl Med. 1995 Jul;36(7):1226-31
pubmed: 7790948
Neuroimage. 2014 May 15;92:225-36
pubmed: 24361666
Nucl Med Commun. 1993 Oct;14(10):862-7
pubmed: 8233229
Ann Neurol. 2003 Jul;54(1):93-101
pubmed: 12838524
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3787-3796
pubmed: 35567626
J Nucl Med. 1994 Jun;35(6):955-63
pubmed: 8195882
Arch Neurol. 1998 Jul;55(7):969-78
pubmed: 9678315
Lancet Neurol. 2006 Jan;5(1):75-86
pubmed: 16361025
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
Mov Disord Clin Pract. 2020 Oct 02;8(2):224-230
pubmed: 33553492
EJNMMI Phys. 2017 Dec;4(1):8
pubmed: 28130765
Neuroimage. 1999 Feb;9(2):179-94
pubmed: 9931268
J Nucl Med. 2002 Oct;43(10):1324-30
pubmed: 12368370
Mov Disord. 2015 Oct;30(12):1600-11
pubmed: 26474317
J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):314-9
pubmed: 9527140
J Nucl Med. 2009 Jun;50(6):893-9
pubmed: 19443601
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5
pubmed: 10984517
Neuroimage Clin. 2016 Feb 23;12:e1-e9
pubmed: 27995072
Q J Nucl Med Mol Imaging. 2012 Feb;56(1):17-26
pubmed: 22460157
Neuroimage. 2016 May 15;132:334-343
pubmed: 26915497
Acta Neurol Scand. 2012 Jul;126(1):12-6
pubmed: 21916850
Mov Disord. 2021 May;36(5):1229-1237
pubmed: 33449392
Neuroimage Clin. 2017 Aug 26;16:539-544
pubmed: 29868437
Front Neurol. 2018 Mar 23;9:156
pubmed: 29628907
J Cheminform. 2014 Mar 29;6(1):10
pubmed: 24678909
Cereb Cortex. 2004 Jan;14(1):11-22
pubmed: 14654453
Front Neurol. 2020 Aug 04;11:791
pubmed: 32849237
J Neurol Sci. 1996 Mar;136(1-2):169-73
pubmed: 8815166
J Nucl Med. 1998 Sep;39(9):1500-8
pubmed: 9744331
BioData Min. 2017 Dec 8;10:35
pubmed: 29234465
Neurology. 2016 Feb 9;86(6):566-76
pubmed: 26764028
Am J Nucl Med Mol Imaging. 2012;2(4):475-82
pubmed: 23145363
Brain. 2011 Nov;134(Pt 11):3146-66
pubmed: 21810889
Eur Radiol. 2021 Sep;31(9):7003-7011
pubmed: 33686474
J Neurol Neurosurg Psychiatry. 1995 Dec;59(6):597-600
pubmed: 7500096
Neurologist. 2009 Jan;15(1):6-16
pubmed: 19131852
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1885-1912
pubmed: 32388612
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Ann Transl Med. 2019 Dec;7(23):773
pubmed: 32042789
Neuroimage. 2004 Jul;22(3):1060-75
pubmed: 15219578